E.V. BOBYKIN, O.V. MOROZOVA, R.V. BUSLAEV

Ural State Medical University, 3 Repina Str., Yekaterinburg, Russian Federation, 620028

 Bobykin E.V. — Cand. Med. Sc., Associate Professor of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: oculist.ev@gmail.com

Morozova O.V. — ophthalmologist, applicant of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: oculist.ev@gmail.com

Buslaev R.V. — clinical resident of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: r.buslaev@bk.ru

The data are presented of a retrospective analysis of antiangiogenic therapy with ranibizumab and aflibercept (247 patients aged from 24 to 92 years for the period from 2010 to 2017) based on the recorded indications. The mean follow-up was 19.5±1.2 months with the average number of intravitreal injections of angiogenesis inhibitors 5.0±0.3. Monitoring was ceased (mainly in the first two years of treatment) by 136 (55.1%) people. The longest follow-up (30.5±3.1 months) and the best percentage of patients for whom the monitoring was continued (76.7%) were recorded in myopic choroidal neovascularization. The worst results were noted with diabetic macular edema — 14.0±4.5 months and 33.3% of patients, respectively. Other factors predisposing to long-term anti-angiogenic therapy were female gender, relatively young age of the patient and high initial visual acuity. The obtained results generally correlate with the results of a meta-analysis of ranibizumab in clinical trials (34 trials lasting from 3 to 24 months, 7006 people): the proportion of patients who prematurely terminated participation was 12.7%, the highest percentage of departed patients was observed at «wet» age-related macular degeneration (14.9%), the lowest — with myopic choroidal neovascularization (4.6%).

Key words: duration of treatment, neovascularization, anti-VEGF therapy, ranibizumab, real clinical practice.

REFERENCES

1. Jacob J., Brié H., Leys A., et al. Six-year outcomes in neovascular age-related macular degeneration with ranibizumab. Int J Ophthalmol, 2017, no. 10(1), pp. 81–90. DOI: 18240/ijo.2017.01.14
2. Rofagha S., Bhisitkul R.B., Boyer D.S., et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology, 2013, no. 120, pp. 2292-2299.
3. Calvo P., Abadia B., Ferreras A., et al. Long-Term Visual Outcome in Wet Age-Related Macular Degeneration Patients Depending on the Number of Ranibizumab Injections. Journal of Ophthalmology, 2015, Article ID 820605, 5pp. http://dx.doi.org/10.1155/2015/820605.
4. Bikbov M.M., Faizrakhmanov R.R., Yarmukhametova A.L. Vozrastnaja makuljarnaja degeneracija [Age-related macular degeneration], 2013. 196 p.
5. Korotkikh A., Bobykin E.V., Nazarova N.S., et al. Long-term outcomes of anti-angiogenic therapy for macular neovascular disorders. Vestnik oftal’mologii, 2016, no. 132(1), pp. 76-84. (in Russ.). DOI: 10.17116/oftalma2016132176-84.
6. Maguire M.G., Martin D.F., et al. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology, 2016, no. 123(8), pp. 1751-61. doi: 10.1016/j.ophtha.2016.03.045.
7. Tschuor P., Pilly B., Venugopal D., et al. Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefes Arch Clin Exp Ophthalmol, 2013, no. 251(10), pp. 2327-30. doi: 10.1007/s00417-013-2332-5.
8. Holz F.G., Tadayoni R., Beatty S., et al. Multi-Country Real-Life Experience of Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration. Br J Ophthalmol, 2014, no. 99(2), pp. 220-226. DOI: 10.1136/bjophthalmol-2014-305327.
9. Bobykin E.V. The influence of patient compliance with antiangiogenic therapy on its efficacy for neovascular age-related macular degeneration. Vestnik oftal’mologii, 2014, no. 130(4), pp. 88-96. (in Russ.).
10. Clinical trial results website RFB002/ranibizumab. URL: https://www.novctrd.com/CtrdWeb/searchbyproduct.nov#R+0+.